Table 2

Results of the univariate linear regression analyses of FSS on sociodemographic, clinical and self-reported health status

VariableβSEt Valuep ValueR2 (%)
Sex (male vs female)−1.610.25−6.46<0.0017.7
Hypertension ever (yes vs no)0.980.293.380.0082.25
Cancer ever (yes vs no)0.750.551.370.170.47
Arthritis duration0.020.0131.400.160.39
Psoriasis duration0.
No of active joints0.110.0138.50<0.00112.7
No of swollen joints0.090.032.860.0041.62
Average grip strength in both hands (mm Hg)−0.010.002−8.39<0.00112.9
No of damaged joints0.
No of fibromyalgia tender points0.240.0210.7<0.00121.2
Morning stiffness (yes vs no)<0.00111.6
ESR (mm/h)0.030.0073.72<0.0013.0
Haemoglobin (g/l)−0.040.009−4.52<0.0014.3
SF-36 pain−0.070.004−16.46<0.00136.8
SF-36 mental health−0.070.006−13.06<0.00127.4
NSAID ever (yes vs no)1.390.582.390.021.35
DMARD ever (yes vs no)0.420.261.630.100.5
Immunosuppressives ever (yes vs no)1.500.255.97<0.0016.7
Methotrexate ever (yes vs no)1.450.255.78<0.0016.3
Oral steroids ever (yes vs no)1.460.334.43<0.0013.8
  • DMARD, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; FSS, fatigue severity scale; HAQ, health assessment questionnaire; NSAID, non-steroidal anti-inflammatory drugs; PASI, psoriasis area and severity index; SF-36, medical outcome survey short form 36.